A novel cancer treatment combining dichloroacetate, metformin, and navitoclax has demonstrated encouraging results in trials. The treatment targets a shared metabolic vulnerability found in both cancer cells and senescent cells—cells associated with aging. Researchers observed improved survival rates and enhanced physical function in aged mice treated with the compound. This suggests a potential pathway for addressing age-related decline alongside cancer. The drug combination’s efficacy stems from impacting a fundamental weakness common to these cells. Further research is needed to determine the treatment's applicability and safety in humans, but the findings offer a hopeful step forward. This approach might represent a dual benefit, tackling both cancer and age-related frailty.